A combination of chitosan nanoparticles loaded with celecoxib and kartogenin has anti-inflammatory and chondroprotective effects: Results from an in vitro model of osteoarthritis

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Zahra Nabizadeh - , Semnan University of Medical Sciences, Qom University of Medical Sciences (Author)
  • Mahmoud Nasrollahzadeh - , Chair of Biomaterials, University of Qom (Author)
  • Benjamin Kruppke - , Chair of Biomaterials (Author)
  • Davood Nasrabadi - , Semnan University of Medical Sciences (Author)

Abstract

Loading drugs in drug delivery systems can increase their retention time and control their release within the knee cavity. Hence, we aimed to improve the therapeutic efficacy of celecoxib and kartogenin (KGN) through their loading in chitosan nanoparticles (CS NPs). Celecoxib-loaded nanoparticles (CNPs) and KGN-loaded nanoparticles (K-CS NPs) were prepared using the absorption method and covalent attachment, respectively, through an ionic gelation process. The morphology, particle size, zeta potential, polydispersity index (PDI), conjugation efficiency (CE), encapsulation efficiency (EE), the in vitro release of the drug from NPs, as well as MTT and hemolysis assays, were evaluated. Then, the IL-1β-stimulated chondrocytes were treated with CNPs and K-CS NPs, individually or in combination, to explore their potential chondroprotective and anti-inflammatory effects. CNPs and K-CS NPs showed sizes of 352.6 ± 22.5 and 232.7 ± 4.5 nm, respectively, suitable for intra-articular (IA) injection. Based on the hemolysis results, both NPs exhibited good hemocompatibility within the studied range. Results showed that treating IL-1β-pretreated chondrocytes with CNPs or K-CS NPs remarkably limited the negative effects of IL-1β, especially when both types of NPs were used together. Therefore, injecting these two NPs into the knee cavity may improve drug bioavailability, rapidly suppress inflammation and pain, and promote cartilage regeneration. Meanwhile, for the first time, the study investigated the effect of the simultaneous use of celecoxib and KGN to treat osteoarthritis (OA).

Details

Original languageEnglish
Article numbere31058
Number of pages13
JournalHeliyon
Volume10
Issue number10
Publication statusPublished - 30 May 2024
Peer-reviewedYes

External IDs

PubMed 38803939

Keywords

ASJC Scopus subject areas

Keywords

  • Celecoxib, Chitosan nanoparticles, Drug delivery, Kartogenin, Osteoarthritis